AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01051466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
Study NCT02186431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Study NCT02186431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Study NCT03209349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation Sigmoidoscopy
Description: See arm description.
Study NCT03486938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet
Study NCT03486938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101 220 mg tablet
Description: 220 mg AGB101 active compound
Study NCT01366196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
Study NCT01895257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HAI-90Y radioembolization (SIR-spheres injection)
Description: Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan
Study NCT01895257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy LV5FU2
Description: Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure.
Study NCT03023059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Description: See Arm description
Study NCT00598013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatmentchoice Decisional Tool
Description: Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
Study NCT03974360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 334
Description: 100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Study NCT02076633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2+L19TNF
Description: Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
Study NCT03830242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: <Sup>18<Sup>F-FDG PET/CT dynamic scan
Description: The purpose of this study is to carry out \<Sup>18\<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup>18\<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Study NCT03830242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: B-ultrasonography
Description: The purpose of this study is to carry out \<Sup>18\<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup>18\<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Study NCT05014217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mentalization-based Treatment
Description: An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
Study NCT05014217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy-inspired Treatment
Description: A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
Study NCT00072657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
Study NCT00072657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
Study NCT00072657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Seminar
Description: Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
Study NCT00547196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00547196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT00547196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatmentchoice Decisional Tool
Description: Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients and physicians fill out questionnaires on the usual care, Delphi study
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients and physicians fill out questionnaires on the usual care, Delphi study
Study NCT03278197 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interviews with stakeholders
Description: Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
Study NCT02887378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hot clamps
Description: reusable hot biopsy forceps
Study NCT02887378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: normal clamps
Study NCT01567059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tosedostat
Description: Given PO
Study NCT01567059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01567059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT03441984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
Study NCT03441984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
Study NCT03441984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
Study NCT00547196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study NCT00547196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Study NCT00547196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT00547196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Study NCT00547196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00547196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT00547196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study NCT00547196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated total body irradiation
Study NCT04425356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeXT Program
Description: The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
Study NCT03234673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
Study NCT03234673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcipotriol ointment
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
Study NCT03234673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
Study NCT04202471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Cloth
Description: 2% chlorhexidine gluconate cloth
Study NCT01092507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus vaccine (JE-CV)
Description: 0.5 mL, Subcutaneous
Study NCT01092507 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
Description: 0.5 mL, Subcutaneous
Study NCT02601599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support.
Study NCT03082482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials
Description: Self-help smoking cessation materials
Study NCT03082482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials
Description: Self-help smoking cessation materials
Study NCT03082482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
Study NCT03082482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
Study NCT03082482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Proactive phone counseling with a Certified Tobacco Treatment Counselor
Study NCT03082482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered automated treatment
Description: Tailored video clips, text and graphical messages delivered automatically each week to the participant.
Study NCT03468985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT03468985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03468985 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03468985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00326066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Surgery
Description: Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
Study NCT00326066 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cataract surgery only
Description: Subjects will undergo routine cataract surgery only (no stent implant).
Study NCT01055522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1: L19IL2 + Dacarbazine
Description: RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first
Study NCT01055522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: Dacarbazine
Description: Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
Study NCT01055522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM 2: L19IL2 + Dacarbazine
Description: RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first
Study NCT02837068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wheelchair handrail compensator
Description: Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
Study NCT02837068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary wheelchair
Description: Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
Study NCT03302195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Based on patient body weight (UI/kg)
Study NCT03302195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Based on patient body weight (UI/kg)
Study NCT03302195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary bypass pump flow rate
Description: Based on patient body weight (L/min/m2)
Study NCT03302195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary bypass pump flow rate
Description: Based on patient body weight (L/min/m2)
Study NCT01734694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;
Study NCT01734694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftaroline
Description: Dose based on package insert labeling~CrCL > 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;
Study NCT01734694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h
Study NCT01734694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg IV/PO q12h
Study NCT03061383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine based toothpaste
Description: toothpaste
Study NCT03061383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8% strontium acetate based toothpaste
Description: toothpaste
Study NCT03061383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: toothpaste
Study NCT04406194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVICOVIR 200 mg Film Tablet
Description: FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
Study NCT04406194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 mg Film Tablets
Description: AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
Study NCT01822327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: CRA plus Vouchers contingent on drug abstinence with values the same across all patients
Study NCT01822327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
Study NCT01822327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: CRA plus Vouchers earned independent of cocaine use
Study NCT00892866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies